@article{fb14a1cbe3954d8e8479054ba6dee090,
title = "What we learn about bipolar disorder from large-scale neuroimaging: Findings and future directions from the ENIGMA Bipolar Disorder Working Group",
abstract = "MRI-derived brain measures offer a link between genes, the environment and behavior and have been widely studied in bipolar disorder (BD). However, many neuroimaging studies of BD have been underpowered, leading to varied results and uncertainty regarding effects. The Enhancing Neuro Imaging Genetics through Meta-Analysis (ENIGMA) Bipolar Disorder Working Group was formed in 2012 to empower discoveries, generate consensus findings and inform future hypothesis-driven studies of BD. Through this effort, over 150 researchers from 20 countries and 55 institutions pool data and resources to produce the largest neuroimaging studies of BD ever conducted. The ENIGMA Bipolar Disorder Working Group applies standardized processing and analysis techniques to empower large-scale meta- and mega-analyses of multimodal brain MRI and improve the replicability of studies relating brain variation to clinical and genetic data. Initial BD Working Group studies reveal widespread patterns of lower cortical thickness, subcortical volume and disrupted white matter integrity associated with BD. Findings also include mapping brain alterations of common medications like lithium, symptom patterns and clinical risk profiles and have provided further insights into the pathophysiological mechanisms of BD. Here we discuss key findings from the BD working group, its ongoing projects and future directions for large-scale, collaborative studies of mental illness.",
keywords = "ENIGMA, MRI, bipolar disorder, cortical surface area, cortical thickness, mega-analysis, meta-analysis, neuroimaging, psychiatry, volume",
author = "{ENIGMA Bipolar Disorder Working Group} and Ching, {Christopher R.K.} and Hibar, {Derrek P.} and Gurholt, {Tiril P.} and Abraham Nunes and Thomopoulos, {Sophia I.} and Christoph Ab{\'e} and Ingrid Agartz and Brouwer, {Rachel M.} and Cannon, {Dara M.} and {de Zwarte}, {Sonja M.C.} and Eyler, {Lisa T.} and Pauline Favre and Tomas Hajek and Haukvik, {Unn K.} and Josselin Houenou and Mikael Land{\'e}n and Lett, {Tristram A.} and Colm McDonald and Leila Nabulsi and Yash Patel and Pauling, {Melissa E.} and Tomas Paus and Joaquim Radua and Soeiro-de-Souza, {Marcio G.} and Giulia Tronchin and {van Haren}, {Neeltje E.M.} and Eduard Vieta and Henrik Walter and Zeng, {Ling Li} and Martin Alda and Jorge Almeida and Dag Aln{\ae}s and Silvia Alonso-Lana and Cara Altimus and Michael Bauer and Baune, {Bernhard T.} and Bearden, {Carrie E.} and Marcella Bellani and Francesco Benedetti and Michael Berk and Bilderbeck, {Amy C.} and Blumberg, {Hilary P.} and Erlend B{\o}en and Irene Bollettini and {del Mar Bonnin}, Caterina and Paolo Brambilla and Canales-Rodr{\'i}guez, {Erick J.} and Xavier Caseras and Sophia Frangou and Stein, {Dan J.}",
note = "Funding Information: O. A. A. received Speaker's honorarium from Lundbeck and is a consultant for HealthLytix. M. B. was supported by an unrestricted grant from AstraZeneca. A. C. B. is a full‐time employee of P1vital Ltd. C. R. K. C. and P. M. T. have received partial research support from Biogen, Inc. (Boston, USA) for work unrelated to the topic of this manuscript. T. E. has received a speaker's fee from Lundbeck. G. M. G. is a NIHR Emeritus Senior Investigator, holds shares in P1vital and P1Vital products and has served as consultant, advisor or C. M. E. speaker in the last 3 years for Allergan, Angelini, Compass pathways, MSD, Janssen, Lundbeck (/Otsuka or /Takeda), Medscape, Minerva, P1Vital, Pfizer, Sage, Servier, Shire, Sun Pharma. D. P. H. is a full‐time employee of Genentech, Inc. A. M. M. has received research support from the Eli Lilly, Janssen and The Sackler Trust. J. C. S. has participated in research funded by Forest, Merck, BMS, and GSK and has been a speaker for Pfizer and Abbott. Marsal Sanches has received research grants from Janssen. All other authors from this site report no conflicts of interest to declare. D. J. S. has received research grants and/or consultancy honoraria from Lundbeck and Sun. E. V. has received grants and served as consultant, advisor or CME speaker for the following entities (work unrelated to the topic of this manuscript): AB‐Biotics, Abbott, Allergan, Angelini, Dainippon Sumitomo Pharma, Galenica, Janssen, Lundbeck, Novartis, Otsuka, Sage, Sanofi‐Aventis, and Takeda. Funding Information: The S{\~a}o Paulo (Brazil) studies have been supported by grants from FAPESP‐Brazil (#2009/14891‐9, 2010/18672‐7, 2012/23796‐2 & 2013/03905‐4), CNPq‐Brazil (#478466/2009 & 480370/2009), the Wellcome Trust (UK) and the Brain & Behavior Research Foundation (2010 NARSAD Independent Investigator Award granted to Geraldo F. Busatto). C. A. Z. was supported by Intramural Research Program, National Institute of Mental Health. L.‐L. Z. was supported by National Natural Science Foundation of China (61722313), Fok Ying Tung Education Foundation (161057), and Science & Technology Innovation Program of Hunan Province (2018RS3080). Lastly, we would like to thank all of the ENIGMA Consortium Working Group Members for all their efforts in helping this international consortium effort thrive. Publisher Copyright: {\textcopyright} 2020 The Authors. Human Brain Mapping published by Wiley Periodicals LLC.",
year = "2022",
month = jan,
doi = "10.1002/hbm.25098",
language = "English",
volume = "43",
pages = "56--82",
journal = "Human Brain Mapping",
issn = "1065-9471",
publisher = "Wiley-Liss Inc.",
number = "1",
}